Introduction {#S0001}
============

Diabetes mellitus (DM) is a chronic disease characterized by high blood glucose, which consists of two main forms insulin-dependent DM (type 1) and non-insulin-dependent DM (type 2).[@CIT0001] Over the past decades, the incidence of type 2 diabetes mellitus (T2DM) has significantly increased in the world, especially in developing country.[@CIT0002] The risk factors of T2DM include family history, lack of exercise, unhealthy diet, overweight, and obesity.[@CIT0003] In addition, high-fat diet (HFD) is associated with the disruption of intestinal barrier, immune response, and/or insulin resistance state, resulting in the increasing risk of T2DM.[@CIT0004] Therefore, it is necessary to focus on HFD-induced hyperglycemia.

Patients with T2DM are generally accompanied by various complications, such as cardiovascular diseases, diabetic neuropathy, nephropathy, and retinopathy.[@CIT0005] Diabetic nephropathy (DN) is a microvascular complication of DM, which is the leading cause of end-stage renal disease. Inadequate glucose control is the most common reason for the occurrence and development of DN.[@CIT0006] DN is charactered by podocytes and glomerular enlargement, interstitial fibrosis or tubular atrophy, microalbuminuria increase, and decline in glomerular filtration rate.[@CIT0007],[@CIT0008] Importantly, renal fibrosis is one of the prominent features of DN, which is the main reason for high morbidity and mortality of DN.[@CIT0009],[@CIT0010] In renal fibrosis, transforming growth factor-Beta (TGF-β) is a major regulator to promote the fibrosis.[@CIT0009] Chronic kidney diseases are characterized by the accumulation of extracellular matrix (ECM) components in the glomeruli.[@CIT0011] Fibronectin is expressed in the ECM, the accumulation of which in the glomeruli is associated with degradation of renal function in patients with DN.[@CIT0012] In addition, type II collagen is one of the main components of the ECM.[@CIT0013] Fibronectin accretion could lead to an upregulation of collagen in patients with diabetes.[@CIT0014] Current treatments of DN are targeted on controlling hyperglycemia and hypertension, as well as inhibiting the renin-angiotensin system. However, these traditional therapies are not optimal.[@CIT0015],[@CIT0016] Therefore, it is necessary to find more effective methods and drugs for the treatment of DN.

A medicinal plant *Silybum marianum* was commonly used as a hepatoprotective medication to treat jaundice and enlarged liver and spleen.[@CIT0017] Silibinin (Silybin) ([Figure 1A](#F0001){ref-type="fig"}), a non-toxic polyphenolic flavonoid, is the main biologically active component extracted from *S. marianum*.[@CIT0018] It was reported that silibinin has anti-inflammation, antifungal, antioxidant, and anti-cancer effect.[@CIT0019]--[@CIT0022] In addition, previous study had revealed that silibinin could be beneficial for T2DM because of its inhibitory effect on glucose-6-phosphatase and gluconeogenesis.[@CIT0023] Moreover, silibinin ameliorates DN via preventing kidney injury, oxidant stress, and activating AKT pathway.[@CIT0024] However, the effect of silibinin on renal fibrosis of DN remains unclear. In the present study, we explored the effect of silibinin on renal fibrosis in vitro and in vivo, and investigated the underlying molecular mechanism.Figure 1Cytotoxicity of silibinin on HRGECs. (**A**) Silibinin chemical structure. (**B**) HRGECs were treated with 0, 25, 50, 75, and 100 μM silibinin for 72 hrs, and cell viability was determined by MTT assay. (**C**) HRGECs were treated with 0, 50, 75, and 100 μM silibinin for 72 hrs, and cell apoptosis was analyzed by flow cytometry. (**D**) The quantification of percentage of apoptotic cells. Each sample was tested in triplicate. \**P*\<0.05 compared with control group;\*\**P*\<0.01 vs 0 μM group.**Abbreviation:** HRGECs, human renal glomerular endothelial cells.

Materials and methods {#S0002}
=====================

Cell culture {#S0002-S2001}
------------

Human renal glomerular endothelial cells (HRGECs) were obtained from American Type Culture Collection (ATCC, Manassas, VA, USA). The cells were cultured in RPMI-1640 medium (Thermo Fisher Scientific, Inc., Waltham, MA, USA) supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin (All from Gibco, Thermo Fisher Scientific, Inc., Waltham, MA, USA) and maintained in an incubator at 37°C with 5% CO~2~. To establish in vitro renal fibrosis model, HRGECs were seeded into six-well plates. When cell confluence reached nearly 80%, the cells were treated with 100 nM recombinant human TGF-β1 (Pepro Tech, Rocky Hill, NJ, USA) for 48 hrs.

Cell viability {#S0002-S2002}
--------------

Cell viability was analyzed by using MTT assay (Beyotime, Shanghai, China). The cells were seeded in 96-well plates at the density of 2×10^3^ cells/well. After treatment of silibinin (0, 25, 50, 75, and 100 μM) for 72 hrs, 10 μL MTT solution was added into each well and incubated for another 4 hrs. Then, the cells were added with 100 μL Formazan dissolving solution. The absorbance of cell was determined at 570 nm using a microplate reader (Thermo Fisher Scientific, Inc., Waltham, MA, USA).

Cell apoptosis {#S0002-S2003}
--------------

Cell apoptosis was determined by flow cytometry using FITC Annexin V Apoptosis Detection Kit I (BD Biosciences, Franklin Lakes, NJ, USA). Briefly, after treatment with various concentrations of silibinin (0, 50, 75, and 100 μM) for 72 hrs, the cells were harvested (1×10^6^ cells/mL), washed twice with PBS and resuspended in Binding Buffer. 5 μL FITC Annexin V and 5 μL PI were incubated with 100 μL cell solution at room temperature for 15 mins in the dark. The staining cells were analyzed by flow cytometry using Gallios instrument (Beckman Coulter, Miami, FL, USA). The percentage of apoptotic cells was quantified.

Reverse transcription-quantitative polymerase chain reaction {#S0002-S2004}
------------------------------------------------------------

Total RNA was extracted by using TRIzol reagent (Invitrogen, Thermo Fisher Scientific, Inc.). RNA integrity was measured by agarose gel electrophoresis. Then, the reverse transcription was conducted by using PrimeScript 1st Strand cDNA Synthesis Kit (Takara, Dalian, China). PCR reactions were carried out by SYBR Premix Ex Taq II (Takara, Dalian, China) with Applied Biosystems 7500 Real-Time PCR System (Applied Biosystems; Thermo Fisher Scientific, Inc.). The specific primers used were Collagen I F: 5ʹ-CGACGGGAGCAGCATTAGCA-3ʹ, R: 5ʹ-GCGCAGGGGCAAAATTCGAG-3ʹ; Fibronectin F: 5ʹ-CGGGAGCCTCGAAGAGCAAG-3ʹ, R: 5ʹ-GTAAAGCGCGCACACACTCG-3ʹ; α-SMA, F: 5ʹ-CTGTGGAACCAGCCTTGCCA-3ʹ, R: 5ʹ-TTTGGTGCAGCCCAGTGGAG-3ʹ; GAPDH, F: 5ʹ-TCATCCCTGCATCCACTGGT-3ʹ, R: 5ʹ-CTGGGATGACCTTGCCCA-3ʹ. The PCR conditions were as follows: 95°C for 30 s, followed by 40 cycles of 95°C for 5 s and 60°C for 34 s. The relative expression of gene was calculated using 2^−ΔΔCt^ method by normalizing to GAPDH expression.

Western blot {#S0002-S2005}
------------

The cells were lysed using RIPA lysis buffer (Beyotime, Shanghai, China) on the ice. The concentration of the protein was quantified using the BCA Protein Assay Kit (Beyotime, Shanghai, China). A total of 30 μg of protein was separated by SDS-PAGE and transferred onto PVDF membranes (Beyotime, Shanghai, China). After blocking with 5% skim milk, the membranes were incubated with primary antibodies (anti-Collagen I: ab34710, 1:1,000; anti-Fibronectin: ab2413, 1:1,000; anti-α-SMA, ab5694, 1:1,000; anti-p-IkB, ab133462, 1:10,000; anti-p-p65, ab86299, 1:2,000; anti-GAPDH, ab181602, 1:10,000, Abcam, Cambridge, MA, USA) at 4°C overnight, and then incubated with secondary antibodies (Goat Anti-Rabbit IgG: ab205718, 1:2,000, Abcam, Cambridge, MA, USA) at room temperature for 1 hr. The bands of proteins were visualized using BeyoECL Plus (Beyotime, Shanghai, China) and examined using IPP Image-Pro Plus software. GAPDH was used as the internal control.

Immunofluorescence staining {#S0002-S2006}
---------------------------

After exposure to TGF-β1 and silibinin, the cells were fixed with 4% paraformaldehyde for 20 mins, permeabilized with 1% Triton X for 20 mins. After blocking with 5% skim milk, the cells were incubated with antibody against NF-κB (ab131546, 1:200, Abcam, Cambridge, MA, USA) at 4°C overnight. On the second day, the cells were incubated with goat-anti-rabbit IgG H&L secondary antibody, ab150077, 1:1,000, Abcam, Cambridge, MA, USA for 50 mins at 37°C, then incubated with DAPI for 10 mins at 37°C in the dark. Immunofluorescence was visualized under fluorescence microscope (Olympus, Tokyo, Japan).

Immunohistochemistry staining {#S0002-S2007}
-----------------------------

The paraffin tissue sections were cut to 4 μm thick. After deparaffinizing with xylene and eluting with 100%, 95% 75%, and 50% alcohol, the sections were boiled with 0.01 M sodium citrate buffer for 8 mins. After blocking with 10% normal goat serum for 1 hr, the sections were incubated with anti-collagen I (ab34710, 1:200, Abcam, Cambridge, MA, USA) overnight at 4°C, and incubated with secondary antibody (Goat Anti-Rabbit IgG: ab205718, 1:2,000, Abcam, Cambridge, MA, USA) for 30 mins at room temperature. Finally, the sections were stained with DAB, counterstained with hematoxylin. Regarding as Masson staining, paraffin sections were stained with Masson composite staining solution, washed with 0.2% acetic acid solution and 5% phosphotungstic acid solution. After stained with bright green staining solution, the tissues were washed with 0.2% acetic acid solution, dehydrated in absolute alcohol. Finally, the tissues were sealed with neutral gum. The results were imaged with a microscope (Olympus, Tokyo, Japan).

Mouse model and silibinin treatment {#S0002-S2008}
-----------------------------------

Adult male C57BL/6J mice (6--8 weeks) were selected for this study. Every four mice housed in a cage under regular conditions (12 hrs light/dark cycles) with free access to water and food. Mice were fed two different diets. Randomly selected mice (n=36) fed HFD diet (60% fat, 20% protein, and 20% carbohydrate) for 30 weeks were used to establish hyperglycemia model, and other 12 mice were fed standard diet for 30 weeks. In the next 6 weeks, these mice were divided into four groups: control group (standard diet, n=12); HFD group (HFD diet, n=12); HFD+50 mg/kg silibinin (n=12); and HFD+100 mg/kg silibinin (n=12). Mice in HFD+50 mg/kg silibinin and HFD+100 mg/kg silibinin groups were treated with 50 or 100 mg/kg/day silibinin dissolved in distilled water, while mice in control and HFD groups were treated with equal volume of distilled water. After treatment, bodyweight of each mouse was detected. Fasting glucose was measured by using a glucometer (Roche, Basel, Switzerland). Microalbuminuria was determined by mouse microalbuminuria ELISA Kit (Boyao, Shanghai, China). The kidney of each mouse was dissected, and kidney weight/body weight and area of fibrosis was examined. Renal fibrosis was measured by staining renal sections with Masson staining.[@CIT0025] The area of fibrosis was quantified by measuring the ratio of blue staining area to total glomerular area. The animal experimental protocol was approved by the Ethics Committee of Jining No.1 People's Hospital. National Institutes of Health guide for the care and use of laboratory animals was strictly followed by us.

Statistical analysis {#S0002-S2009}
--------------------

Statistical analysis was performed by using GraphPad Prism software (version 7, La Jolla, CA, USA). The data were presented as mean ± standard deviation (SD) of at least three independent experiments. One-way ANOVA followed by Tukey's test was Student's *t*-test was performed to analyze difference among groups. *P*-value less than 0.05 was considered as a significant difference.

Results {#S0003}
=======

The cytotoxic effect of silibinin on HRGECs {#S0003-S2001}
-------------------------------------------

To investigate the cytotoxic effect of silibinin on HRGECs, MTT assay was performed. As shown in [Figure 1B](#F0001){ref-type="fig"}, As compared to 0 μM group, 25 and 50 μM silibinin did not affect cell viability, while 75 and 100 μM silibinin significantly inhibited cell viability (75 μM: *P*\<0.05; 100 μM: *P*\<0.01). To assess the effect of silibinin on cell apoptosis, flow cytometry was used. The data demonstrated that 75 or 100 μM silibinin evidently increased apoptosis of HRGECs, compared with 0 μM group (*P*\<0.01, [Figure 1C](#F0001){ref-type="fig"} and [D](#F0001){ref-type="fig"}). These data suggested that high concentration of silibinin (≥75 μM) had significant cytotoxicity via inducing apoptosis. Therefore, the nontoxic concentration of 50 μM was selected for further analysis.

Silibinin reversed TGF-β1-induced fibrosis of endothelial cells in vitro {#S0003-S2002}
------------------------------------------------------------------------

Next, in order to establish cell fibrosis in vitro model, HRGECs were treated with 100 nM TGF-β1, and the expression of fibrotic markers was measured by qPCR and Western blot. As indicated in [Figure 2A](#F0002){ref-type="fig"}--[E](#F0002){ref-type="fig"} TGF-β1 treatment greatly upregulated the mRNA and protein levels of collagen I, fibronectin and α-SMA compared with the control group (*P*\<0.01). In contrast, 50 μM silibinin markedly attenuated the upregulation of collagen I, fibronectin and α-SMA induced by TGF-β1 (*P*\<0.01). These results indicated that silibinin could reverse TGF-β1-induced fibrosis of endothelial cells in vitro.Figure 2Silibinin reversed TGF-β1-induced fibrosis of endothelial cells in vitro. (**A**) The mRNA levels of collagen I, fibronectin, and α-SMA were measured by RT-qPCR, when HRGECs incubation with 100 nM TGF-β1 or/and 50 μM silibinin for 72 hrs. (**B**) The protein expression of collagen I, fibronectin, and α-SMA was examined by Western blot. GAPDH was used as an internal control. The relative protein expression of (**C**) collagen I, (**D**) fibronectin, and (**E**) α-SMA normalized to GAPDH was quantified. Each sample was tested in triplicate. \*\**P*\<0.01 vs control group; ^\#\#^*P*\<0.01 vs TGF-β1 group.**Abbreviations:** RT-qPCR, reverse transcription-quantitative polymerase chain reaction; HRGECs, human renal glomerular endothelial cells.

Silibinin reversed TGF-β1-induced fibrosis of HRGECs via inhibition of the NF-κB pathway in vitro {#S0003-S2003}
-------------------------------------------------------------------------------------------------

The present study further detected the effect of silibinin on p-IκB, p-p65 levels in order to explore the role of NF-κB pathway during TGF-β1-induced renal fibrosis. As illustrated in [Figure 3A](#F0003){ref-type="fig"}--[C](#F0003){ref-type="fig"}, TGF-β1 induced an increased phosphorylation of IκB and p65 (*P*\<0.01), while silibinin attenuated these elevations (*P*\<0.01). In addition, immunofluorescence data demonstrated that TGF-β1 induced NF-κB nuclear translocation was notably inhibited by silibinin ([Figure 3D](#F0003){ref-type="fig"}). These data suggested silibinin reversed TGF-β1-induced fibrosis of HRGECs via inhibition of the NF-κB pathway in vitro.Figure 3Silibinin suppressed TGF-β1-induced renal fibrosis via inhibition of the NF-κB signaling pathway. (**A**) HRGECs were treated with 100 nM TGF-β1 or/and 50 μM silibinin for 72 hrs, and the expressions of p-IκB and p-p65 in cells were detected by Western blot. GAPDH was used as a loading control. The relative protein expression of (**B**) p-IκB and (**C**) p-p65 was quantified. (**D**) Immunofluorescence analysis of NF-κB. Each sample was tested in triplicate. \*\**P*\<0.01 vs control group; ^\#\#^*P*\<0.01 vs TGF-β1 group.**Abbreviation:** HRGECs, human renal glomerular endothelial cells.

Silibinin inhibited HFD-induced renal fibrosis of mice in vivo {#S0003-S2004}
--------------------------------------------------------------

To investigate the anti-fibrosis role of silibinin in vivo, HFD-induced renal fibrosis of mice model was established. The result indicated HFD significantly increased body weight of mice, compared with control group (*P*\<0.01), while silibinin had no effect on body weight of mice ([Figure 4A](#F0004){ref-type="fig"}). Similarly, HFD resulted in upregulation of fasting glucose (*P*\<0.01); however, neither 50 mg/kg nor 100 mg/kg silibinin affected fasting glucose in HFD mice ([Figure 4B](#F0004){ref-type="fig"}). Additionally, kidney weight/body weight and microalbuminuria of HFD mice were greatly increased, which were markedly reduced in HFD +50 mg/kg silibinin (kidney weight/body weight: *P*\<0.05; microalbuminuria: *P*\<0.01) and HFD+100 mg/kg silibinin groups (kidney weight/body weight: *P*\<0.01; microalbuminuria: *P*\<0.01, [Figure 4C](#F0004){ref-type="fig"} and [D](#F0004){ref-type="fig"}). Furthermore, the data of HE staining demonstrated that the status and area of fibrosis in kidneys were markedly increased in HFD mice, while fibrosis area induced by HFD was notably reversed by silibinin (50 mg/kg: *P*\<0.05; 100 mg/kg: *P*\<0.01) ([Figure 4E](#F0004){ref-type="fig"}--[G](#F0004){ref-type="fig"}). All these results suggested that silibinin inhibited HFD-induced renal fibrosis of mice in vivo.Figure 4Silibinin inhibited HFD-induced renal fibrosis of mice in vivo. (**A**) Effect of HFD or/and silibinin on body weight of mice. (**B**) Fasting glucose evaluation of mice was detected by a glucometer. (**C**) Effect of 50 or 100 mg/kg silibinin on kidney weight/body weight of HFD mice. (**D**) Microalbuminuria measurement of mice from control, HFD, HFD+50 mg/kg silibinin, and HFD+100 mg/kg silibinin groups. (**E**) H&E staining of mice kidney tissues in control, HFD, HFD+50 mg/kg silibinin, and HFD+100 mg/kg silibinin groups. (**F**) Masson staining of mice kidney tissues in control, HFD, HFD+50 mg/kg silibinin, and HFD+100 mg/kg silibinin groups. (**G**) The area of fibrosis was quantified. Each sample was tested in triplicate. \*\**P*\<0.01 vs control group; ^\#^*P*\<0.05 vs HFD group; ^\#\#^*P*\<0.01 vs HFD group.**Abbreviation:** HFD, high-fat diet.

Silibinin reversed HFD-induced upregulation of collagen I, fibronectin, and p-p65 in vivo {#S0003-S2005}
-----------------------------------------------------------------------------------------

Finally, the expression of collagen I, fibronectin, and p-p65 was measured in mice kidneys. Immunohistochemistry results demonstrated that collagen I expression was increased under HFD condition, while 50 or 100 mg/kg silibinin decreased its expression significantly ([Figure 5A](#F0005){ref-type="fig"}). The data of Western blot consistent with immunohistochemistry (100 mg/kg: *P*\<0.01; [Figure 5B](#F0005){ref-type="fig"} and [C](#F0005){ref-type="fig"}). Additionally, the protein expression of fibronectin and p-p65 was upregulated in the HFD group, which was downregulated by 50 or 100 mg/kg silibinin (*P*\<0.01; [Figure 5B](#F0005){ref-type="fig"}, [D](#F0005){ref-type="fig"}, and [E](#F0005){ref-type="fig"}). These results further demonstrated that silibinin reversed HFD-induced upregulation of collagen I, fibronectin, and p-p65 in vivo via inhibition of the NF-κB pathway.Figure 5Silibinin attenuates renal fibrosis in vivo by inhibition of the NF-κB pathway. (**A**) Immunohistochemistry analysis of collagen I. (**B**) The protein expression of collagen I, fibronectin, and p-p65 was measured by Western blot. GAPDH was used for the normalization. Quantification of the ratio of (**C**) collagen I, (**D**) fibronectin, and (**E**) p-p65 protein levels to GAPDH. Each sample was tested in triplicate. \*\**P*\<0.01 vs control group; ^\#\#^*P*\<0.01 vs HFD group.**Abbreviation:** HFD, high-fat diet.

Discussion {#S0004}
==========

In the present study, we explored the effects of silibinin on DN. We found that silibinin reduced the expression of main markers of fibrosis, represented by collagen I, fibronectin, and α-SMA in TGF-β1 treated HRGECs. Additionally, silibinin also decreased kidney hypertrophy and renal fibrosis status in HFD-induced renal fibrosis of mice. Moreover, silibinin downregulated the protein levels of p-IκB, p-p65, and NF-κB. These results suggested that silibinin plays an important role in renal fibrosis of DN through inactivation of the NF-κB pathway.

With the development of the society, HFD is common. However, HFD seriously threaten human health, such as causing gastrointestinal diseases,[@CIT0026] obesity[@CIT0027], and hyperinsulinemia.[@CIT0028] Obesity is a key factor in the development of DN. There is no effective treatment for DN. Previous studies have reported that some compounds as able to prevent DN. For example, thymol afforded protection against HFD-induced DN.[@CIT0029] *Myrciaria cauliflora* extracts are benefit to DN through inhibiting Ras/PI3K/AKT pathway and suppressing kidney fibrosis-related protein.[@CIT0030] In addition, Ramulus mori polysaccharides exerts antioxidant effect to protect kidney injury and improve the renal function of diabetic rats.[@CIT0031] Silibinin is a kind of flavonoid compound, which has biological activities and medicinal value. Researches have revealed that the effectiveness of silibinin in diabetic complications including neuropathy, hepatopathy, cardiomyopathy, nephropathy, and so on.[@CIT0032] Silibinin could protect high glucose-induced podocyte injury through preventing oxidant stress.[@CIT0033] Moreover, silibinin prevents kidney injury, attenuates oxidant stress, decreases serum insulin level to ameliorate DN.[@CIT0024] Besides, some researches have revealed that silibinin delays the process of fibrosis, including but not limited to intestines,[@CIT0034] lung[@CIT0035], and liver.[@CIT0036] In the present study, silibinin was shown to attenuate renal fibrosis in vitro. 50 μM silibinin downregulated TGF-β1-induced upregulation of the expression of collagen I, fibronectin, and α-SMA. Moreover, silibinin decreased HFD-induced the ratio of kidney weight to body weight, microalbuminuria, and the area of renal fibrosis. These results all demonstrated that silibinin is able to attenuate renal fibrosis in vitro and in vivo.

NF-κB transcription factor regulates various components such as pro-inflammatory cytokines, chemokines, adhesion molecules, and inducible enzymes to adjust the immune response.[@CIT0037] Activation of NF-κB signaling pathway involved in the development of inflammation, atherosclerosis, Alzheimer's disease, and human cancers.[@CIT0038] Silibinin inhibits the progression of several diseases through this pathway. Silibinin inhibits lipopolysaccharide-induced lung injury, exerts anti-inflammatory effect through suppressing NF-κB signaling pathway.[@CIT0039] In addition, silibinin suppresses colorectal cancer growth and progression through the NF-κB pathway against chronic inflammation.[@CIT0040] Previous studies reported that NF-κB signaling pathway is involved in chronic kidney disease, which mediated inflammation and renal fibrosis.[@CIT0041] Such as protein kinase CK2α and sphingosine kinase 1 ameliorate diabetic renal inflammatory fibrosis through the NF-κB pathway.[@CIT0042],[@CIT0043] In the present study, silibinin decreased the upregulation of phosphorylation of IκB and P65 induced by TGF-β1. In addition, Silibinin prevented an increase in NF-κB activity. Meanwhile, silibinin suppressed the protein level of p-p65 in vivo. These findings suggested that silibinin inhibits renal fibrosis via inhibition of NF-κB. Three major glomerular cell types are involved in the fibrotic process including podocytes or visceral epithelial cells, mesangial cells, and endothelial cells.[@CIT0011] However, this study focused only on the role of silibinin on endothelial cells. Therefore, further studies are needed to clarify the role of silibinin on podocytes or visceral epithelial cells and mesangial cells.

Conclusion {#S0005}
==========

This study for the first time to demonstrate that silibinin attenuated renal fibrosis of DN in vitro and in vivo via inhibition of NF-κB. These findings indicated that silibinin might serve as an effective agent for delaying the treatment of DN.
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